The Development
Webster Equity Partners, a Massachusetts-based private equity firm specializing in healthcare, has finalized the sale of InBloom Autism Services, a prominent provider of applied behavior analysis (ABA) and autism therapy. While Webster Equity Partners did not publicly disclose the buyer or the financial terms of the transaction, media reports from Axios indicate that Elysium Management, the family office associated with Leon Black, co-founder and former CEO of Apollo Global Management, acquired InBloom Autism Services for a reported $75 million. An executive from Webster Equity Partners confirmed the completion of the sale.
The transaction, which appears to have concluded near the end of 2025, marks the culmination of Webster Equity Partners’ ownership, which began with their acquisition of InBloom Autism Services in 2018. This seven-year hold period is notably longer than the typical private equity investment horizon, which often averages around five years. The extended duration may have been influenced by broader market conditions, including the onset of the COVID-19 pandemic and a significant deceleration in deal volumes observed in 2023 across the behavioral health sector.
Calex Partners, a New York City-based mergers and acquisitions advisory firm, served as the exclusive financial advisor to InBloom Autism Services for this transaction. Calex Partners has a substantial track record in the autism therapy market, having advised on 22 similar deals. Their previous engagements include the acquisition of Proud Moments ABA by Nautic Partners, Behavioral Innovations by Tenex Capital Management, and the sale of the Center for Autism and Related Disorders (CARD) to a consortium that included its founder, Doreen Granpeesheh.
Market Impact
This divestiture by Webster Equity Partners and the acquisition by Elysium Management underscore the continued, albeit evolving, interest of private equity in the ABA therapy market. The reported sale price provides a benchmark for valuations within the sector, particularly for established providers like InBloom Autism Services. The extended hold period for Webster Equity Partners reflects a period of market volatility and adjustment, contrasting with the median hold period for private equity-backed transactions, which The Braff Group reported as 3.8 years at Behavioral Health Business’ Autism Investor Summit East.
The broader market context reveals a challenging environment for deal-making in 2023, with The Braff Group’s data indicating that overall deal volumes decreased by half compared to the previous year. Despite these headwinds, InBloom Autism Services had been identified by Behavioral Health Business in 2024 as a company to watch for a potential sale, signaling its market position and attractiveness to investors. The involvement of a specialized advisory firm like Calex Partners, with its deep experience in the autism therapy space, highlights the complexity and strategic nature of these transactions.
What’s Next
The acquisition by Elysium Management positions InBloom Autism Services under new ownership, potentially signaling a fresh strategic direction for the company. InBloom recently expanded its footprint by opening three new clinics in Connecticut, indicating a continued focus on growth and service delivery. This transaction is likely to be closely watched by other ABA providers, private equity firms, and stakeholders in the behavioral health industry as an indicator of market sentiment and future investment trends.
Fast Facts
| Key Point | Why It Matters for ABA |
|---|---|
| Webster Equity Partners sold InBloom Autism Services | Signals continued private equity activity and portfolio management in the ABA sector. |
| Elysium Management acquired InBloom for $75 million | Provides a valuation benchmark for established ABA therapy providers. |
| Calex Partners advised on the deal (22 similar transactions) | Highlights the role of specialized M&A advisors in navigating complex behavioral health deals. |
| Seven-year hold period for Webster Equity Partners | Reflects market shifts and extended investment timelines compared to the median 3.8 years. |
| 2023 deal volume decreased by half | Contextualizes the transaction within a period of broader market slowdown for behavioral health investments. |
Expert Perspective
This transaction demonstrates sustained investor confidence in the ABA therapy market, even amidst fluctuating private equity deal volumes and extended hold periods.
Source: bhbusiness.com
